Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

57.1%

4 terminated/withdrawn out of 7 trials

Success Rate

42.9%

-43.6% vs industry average

Late-Stage Pipeline

29%

2 trials in Phase 3/4

Results Transparency

200%

6 of 3 completed trials have results

Key Signals

6 with results

Enrollment Performance

Analytics

Phase 1

3(42.9%)

Phase 3

2(28.6%)

Phase 2

2(28.6%)

7Total

Phase 1(3)

Phase 3(2)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT02663622Phase 2Completed

Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002)

Role: lead

NCT04552704Phase 1Terminated

CD24Fc for the Treatment of Immune Related Adverse Events in Patients With Advanced Solid Tumors, TIRAEC Study

Role: collaborator

NCT04317040Phase 3Completed

Efprezimod Alfa (CD24Fc, MK-7110) as a Non-antiviral Immunomodulator in COVID-19 Treatment (MK-7110-007)

Role: lead

NCT04095858Phase 3Terminated

Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005)

Role: lead

NCT03960541Phase 2Terminated

Efprezimod Alfa (CD24Fc, MK-7110) Administration to Decrease Low-Density Lipoprotein (LDL) and Inflammation in Human Immunodeficiency Virus (HIV) Patients (CALIBER) (MK-7110-003)

Role: lead

NCT02650895Phase 1Completed

Safety Study of Efprezimod Alfa (CD24Fc, MK-7110) When Administered Intravenously in Healthy Adult Subjects (MK-7110-001)

Role: lead

NCT04060407Phase 1Withdrawn

CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI)

Role: lead

All 7 trials loaded